Abstracts - faqs.org

Abstracts

Health

Search abstracts:
Abstracts » Health

Tumor necrosis factor and the Jarisch-Herxheimer reaction

Article Abstract:

A 1996 study has resurrected the idea of using antibodies against tumor necrosis factor (TNF) in the treatment of septic shock. Septic shock occurs when dead or dying bacteria release toxins into a patient's bloodstream that cause shock. It often occurs after the patient receives antibiotics. The study found that giving TNF antibodies to a group of patients with relapsing fever before they received antibiotics reduced the incidence of a severe shock-like reaction called the Jarisch-Herxheimer reaction. However, this reaction is distinct from septic shock, so the results may not be applicable to patients in septic shock.

Author: Munford, Robert S., Beutler, Bruce
Publisher: Massachusetts Medical Society
Publication Name: The New England Journal of Medicine
Subject: Health
ISSN: 0028-4793
Year: 1996
Editorial, Septic shock

User Contributions:

Comment about this article or add new information about this topic:

CAPTCHA


Prevention of Jarisch-Herxheimer reactions by treatment with antibodies against tumor necrosis factor alpha

Article Abstract:

Administering antibodies against tumor necrosis factor alpha (TNF-alpha) to patients with relapsing fever prior to antibiotics could reduce the incidence of Jarisch-Herxheimer reaction. This inflammatory reaction often follows the use of antibiotics and is characterized by fever and high blood pressure. The reaction occurred in only half the patients who were given an intravenous infusion of TNF-alpha antibodies prior to antibiotic treatment for relapsing fever. Ninety percent of the control group who received a placebo developed the reaction. This treatment could be used in patients with septic shock.

Author: Lalloo, David G., Fekade, Daniel, Knox, Kyle, Hussein, Kebede, Melka, Amsel, Coxon, Ruth E., Warrell, David A.
Publisher: Massachusetts Medical Society
Publication Name: The New England Journal of Medicine
Subject: Health
ISSN: 0028-4793
Year: 1996
Inflammation

User Contributions:

Comment about this article or add new information about this topic:

CAPTCHA


The tumor necrosis factor ligand and receptor families

Article Abstract:

Tumor necrosis factor (TNF) is a chemical produced by immune cells called macrophages. It plays an important role in fighting infectious organisms, but it can also damage the body in excess quantities. One of its major actions is to induce cell death. However, it has also been implicated in septic shock, a state of shock caused by severe bacterial infection. Antibodies against TNF have not been successful in treating septic shock, but they do reduce the symptoms of rheumatoid arthritis.

Author: Beutler, Bruce, Bazzoni, Flavia
Publisher: Massachusetts Medical Society
Publication Name: The New England Journal of Medicine
Subject: Health
ISSN: 0028-4793
Year: 1996
Cytokines

User Contributions:

Comment about this article or add new information about this topic:

CAPTCHA


Subjects list: Prevention, Complications and side effects, Physiological aspects, Anti-infective agents, Drug therapy, Tumor necrosis factor, Relapsing fever
Similar abstracts:
  • Abstracts: Malone urges trusts to find quick pay deal solutions. RCN out on a limb as unions accept deal. NHS personnel chief sounds pay deal alert
  • Abstracts: Second-trimester echogenic bowel and intraamniotic bleeding: association between fetal bowel echogenicity and amniotic fluid spectrophotometry at 410 nm
  • Abstracts: Plasminogen activators and their inhibitors in synovial fluids from normal, osteoarthritis, and rheumatoid arthritis knees
  • Abstracts: Successful negotiators know the process is key. Battle tactics may be needed to get negotiation back on track
  • Abstracts: The American public and the gun control debate. The public and the war on illicit drugs. The Public and the Comprehensive Tobacco Bill
This website is not affiliated with document authors or copyright owners. This page is provided for informational purposes only. Unintentional errors are possible.
Some parts © 2025 Advameg, Inc.